Navigation Links
Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
Date:1/6/2014

BSA) coverage of lesional areas on the skin in patients with EB (Simplex, Recessive Dystrophic, or Junctional (non-Herlitz)). In addition, improvement on pain and itching will also be assessed. Approximately 48 subjects aged six months and older are planned to enroll in the trial, which is being conducted in 7 sites across the US. The study will comprise application of SD-101 cream over the entire body daily for a period of three months.  Patients completing the study will be eligible to continue receiving SD-101 once the study is completed.  Additional information about Study SD-003 can be found at www.clinicaltrials.gov.

"Our patients with EB have few therapeutic options available and none have demonstrated evidence of accelerated closure of chronic wounds, said the study's Principal Investigator, Amy Paller, MD, Walter J. Hamlin Professor and Chair of the Department of Dermatology, Northwestern University Feinberg School of Medicine.  "We look forward to testing this new potential intervention in the double-blind, randomized trial. If the lives of the EB patients are improved with topical use of SD-101 through faster wound healing, as well as decreased pain and itchiness, this cream would be welcomed by our affected families."

"We are very excited that Scioderm has developed this potential therapy to treat some of the more profound symptoms of EB," said Brett Kopelan, MA, Executive Director of the Dystrophic Epidermolysis Bullosa Research Association of America (debra of America).  "The impact on the quality of life of those with EB would be immeasurable if SD-101 was to be proven safe and effective." 

About Epidermolysis Bullosa (EB)

Epidermolysis Bullosa (EB) is a rare genetic connective tissue disorder, with many genetic and symptomatic variations. All forms of EB share the common symptom of fragile skin that blisters and tears from
'/>"/>

SOURCE Scioderm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Scioderm Announces Positive Phase II Data of Topical SD-101 on Wound Closure and Reduction of Lesions and Blisters in Children with Epidermolysis Bullosa (EB)
2. Scioderms Investigational New Drug (IND) Application for SD-101 for Treatment of Epidermolysis Bullosa (EB) Allowed by the FDA
3. Scioderms SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... and STOCKHOLM , Dec. 22, 2014 ... partner Auxilium Pharmaceuticals, Inc. today announced that the Committee ... European Medicines Agency (EMA) has adopted a positive opinion ... the treatment of adult men with Peyronie,s disease with ... 30 degrees at the start of therapy. ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Residents ... Retirement Community, recently showed their generous spirit by ... the Catawba County Parenting Network- Grandparents Raising Grandchildren ... children gathered around the largest Christmas tree on ... presents purchased by residents of the Abernethy Village ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... is 700 smiling little faces this holiday that might ... in monetary donations was given to the various charities ... they incur through the year. Some of the charities ... Haven , Shrine's Children's Hospitals, Toys for Tots and ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:AlignLife Donates Over 700 Toys This Year 2
... THURDSAY, Nov. 17 (HealthDay News) --,Children with sunken chest require ... to plan corrective surgery if necessary, according to experts. ... cage, is one of the most common birth defects of ... children and is rarely life-threatening. The main reason to ...
... , WEDNESDAY, Nov. 16 (HealthDay News) -- As thousands of ... habit as part of the Great American Smokeout on Thursday, ... for success. "The U.S. Public Health Service has twice ... is a combination of counseling/advice, by pharmacists, physicians or quitlines, ...
... Factors such as low hemoglobin levels, increased systolic blood pressure, ... silent cerebral infarcts (SCIs), or silent strokes, in children with ... first-of-its-kind study published online today in ... of Hematology (ASH). Silent strokes are the most ...
... Transsexual individuals who identify themselves as such in the ... commitment to their job than transsexuals who do not, ... Pennsylvania State University. "Trans-parency in the Workplace: ... will appear in an upcoming issue of the ...
... HealthDay Reporter , THURSDAY, Nov. 17 (HealthDay News) -- ... pain, but a new survey shows otherwise. In ... who was suffering from pain, the majority of oncologists ... consider "unacceptable." "There are serious deficiencies in oncologists, ...
... With antibiotic-resistant infections increasingly common, and a dangerous lack ... it,s more important than ever to use existing antibiotics ... educate consumers, health care providers, and policymakers about when ... can do more harm than good, and the tremendous ...
Cached Medicine News:Health News:Sunken Chest Demands Prompt Evaluation, Expert Says 2Health News:Smokeout Day: The Best Ways to Quit 2Health News:Smokeout Day: The Best Ways to Quit 3Health News:Study identifies 'silent' stroke risk factors for children with sickle cell anemia 2Health News:'Trans-parency' in the workplace 2Health News:Cancer Doctors Still Not Great With Patients' Pain 2Health News:Cancer Doctors Still Not Great With Patients' Pain 3Health News:Preserving lifesaving antibiotics today and for the future 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Hinged Ulnar Deviation Splint uses safe, mild ... with ulnar deviation at the MP joints. ... pinch. Radial and ulnar polycentric hinges located ... and extension. Padded, malleable finger rings can ...
... RCAI Dorsal Blocking Splint is constructed of a ... DBS protects the flexor tendons of the hand ... scar tissue development in the later stages of ... dorsally on the hand and positions the wrist ...
Bunell Mini-Modified Safety Finger Pin reduces PIP flexion contractures....
Medicine Products: